Cargando…
Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
This study (NCT01288573) investigated plerixafor’s safety and efficacy in children with cancer. Stage 1 investigated the dosage, pharmacokinetics (PK), pharmacodynamics (PD), and safety of plerixafor + standard mobilization (G-CSF ± chemotherapy). The stage 2 primary endpoint was successful mobiliza...
Autores principales: | Morland, Bruce, Kepak, Tomas, Dallorso, Sandro, Sevilla, Julian, Murphy, Dermot, Luksch, Roberto, Yaniv, Isaac, Bader, Peter, Rößler, Jochen, Bisogno, Gianni, Maecker-Kolhoff, Britta, Lang, Peter, Zwaan, C. Michel, Sumerauer, David, Kriván, Gergely, Bernard, John, Liu, Qianying, Doyle, Eileen, Locatelli, Franco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452813/ https://www.ncbi.nlm.nih.gov/pubmed/32127657 http://dx.doi.org/10.1038/s41409-020-0836-2 |
Ejemplares similares
-
Plerixafor
por: Slater, Susan
Publicado: (2012) -
Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
por: Eiz-Vesper, Britta, et al.
Publicado: (2013) -
Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation
por: Mynarek, Martin, et al.
Publicado: (2013) -
Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2023) -
Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)